Ultimately, we aimed to generate explorative evidence on how their levels might be regulated and their associations with circulating lipids in the setting of human liver regeneration
Key Takeaways Retatrutide (LY3437943) is an investigational weight loss medication developed by Eli Lilly Triple-agonist mechanism: First drug to activate GLP-1, GIP, and glucagon receptors simultaneously Phase 2 results: Up to 24.2% weight loss at 48 weeks (approximately 58 lbs for a 240-lb person) Not FDA-approved: Currently in Phase 3 clinical trials, expected approval in 20272028 How it differs: Outperforms semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in weight loss trials Access now: Clinical trials (free), compounding pharmacies, or research peptide vendors What Is Retatrutide
Assess their flexibility and lead times for custom orders
Mora P, Aroda V, Asong M, et al
A previous study highlighted that they increase nitric oxide production, reduce oxidative stress and promote microvascular recruitment, including in the retina and optic nerve, through direct actions on vascular endothelium
For laboratory and in-vitro research use only
